Lyell (NASDAQ: LYEL) COO sells stock to pay restricted stock taxes

Rhea-AI Filing Summary

Lyell Immunopharma, Inc. (LYEL) reported that its Chief Operating Officer, Stephen J. Hill, had 989 shares of common stock automatically sold on 2026-08-21 at $15.54 per share. According to the disclosure, the sale was made to cover a tax withholding obligation arising from the settlement of vested restricted stock units, leaving 16,816 shares held directly.

Insider Trade Summary

Net Seller: 989 shares

Net Sell 1 txn

Insider Hill Stephen J.

Role Chief Operating Officer

Sold 989 shs ($15K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	989	$15.54	$15K

Holdings After Transaction: Common Stock — 16,816 shares (Direct)

Footnotes (1)

1. F1. Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

Key Figures

Shares sold: 989 shares Sale price per share: $15.54 per share Shares held after transaction: 16,816 shares

3 metrics

Shares sold 989 shares Common stock sale on 2026-08-21 to cover tax withholding

Sale price per share $15.54 per share Price for 989 LYEL common shares sold on 2026-08-21

Shares held after transaction 16,816 shares Direct holdings of Stephen J. Hill following the sale

Key Terms

restricted stock units, tax withholding obligation, open market or private transaction

3 terms

restricted stock units financial

"from settlement of vested restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligation financial

"sold to cover tax withholding obligation from settlement"

open market or private transaction financial

"transaction code description "Sale in open market or private transaction""

FAQ

What insider transaction did LYEL report for Stephen J. Hill on August 21, 2026?

Lyell Immunopharma, Inc. reported that Chief Operating Officer Stephen J. Hill had 989 shares of common stock sold on 2026-08-21 at $15.54 per share, leaving him with 16,816 shares held directly after the transaction.

Was the August 21, 2026 LYEL Form 4 sale by Stephen J. Hill a discretionary trade?

The Form 4 states the 989 shares were automatically sold to cover a tax withholding obligation from settlement of vested restricted stock units, indicating the transaction was tied to equity compensation tax withholding rather than a discretionary open-market sale.

How many LYEL shares does Stephen J. Hill hold after the reported transaction?

After the August 21, 2026 transaction, Chief Operating Officer Stephen J. Hill is reported to hold 16,816 shares of Lyell Immunopharma, Inc. common stock directly, according to the Form 4 filing data.

What price was received per LYEL share in Stephen J. Hill’s August 21, 2026 sale?

The Form 4 reports that the 989 shares of Lyell Immunopharma, Inc. common stock were sold at a price of $15.54 per share in a transaction coded as a sale in an open market or private transaction.

What is the reason for the LYEL share sale reported for Stephen J. Hill?

A footnote explains that the 989 shares of Lyell Immunopharma, Inc. common stock were automatically sold to cover tax withholding obligations arising from the settlement of vested restricted stock units held by Chief Operating Officer Stephen J. Hill.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/25/2026 - 04:06 PM Accepted by SEC EDGAR 08/25/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hill Stephen J.

(Last) (First) (Middle)

C/O LYELL IMMUNOPHARMA, INC.

201 HASKINS WAY

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2026		S		989(1)	D	$15.54	16,816	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.

	/s/ Mark Meltz, Attorney-in-Fact	08/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)